3例转移性去势抵抗性前列腺癌不同转移灶中AR-V7的表达异质性分析  

Heterogeneity of AR-V7 protein expression in different metastases of 3 patients with metastatic castration-resistant prostate cancer

作　　者：尹文莲 陈雪芹[1] 聂玲[1] 张孟尼 曾浩[1] 钟金晶[1] 卫昱燕 周桥[1] 陈铌[1] YIN Wenlian;CHEN Xueqin;NIE Ling;ZHANG Mengni;ZENG Hao;ZHONG Jinjing;WEI Yuyan;ZHOU Qiao;CHEN Ni(Department of Pathology,West China Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西医院病理科,四川成都610041

出　　处：《现代泌尿外科杂志》2021年第8期632-636,654,共6页Journal of Modern Urology

基　　金：国家自然科学基金(No.81872107,No.81872108);四川省科技厅重点研发项目(No.2020YFS0190,No.2020YFS 0191)。

摘　　要：目的报道3例前列腺癌患者初诊及进展为转移性去势抵抗性前列腺癌(mCRPC)后不同部位肿瘤病灶中AR剪切变异体7(AR-V7)表达的异质性。方法收集3例前列腺癌患者初诊穿刺、mCRPC后前列腺原发灶二次穿刺和不同部位转移灶穿刺的石蜡包埋组织进行AR-V7免疫组化染色,观察不同肿瘤组织中AR-V7的表达情况。结果3例患者前列腺原发灶初次穿刺、mCRPC后前列腺二次穿刺及不同部位转移灶中肿瘤细胞含量及AR-V7的表达均存在明显异质性。与初次穿刺相比,其中2例mCRPC后原发灶二次穿刺仅见少量肿瘤或无肿瘤细胞残留。3例患者前列腺癌初次穿刺肿瘤组织均不表达AR-V7,进入mCRPC阶段后,肿瘤原发灶与转移灶中AR-V7表达存在明显差异,不同转移灶之间AR-V7的表达也存在差异。结论mCRPC患者的临床进展可能是由转移灶所致。不同部位转移灶中AR-V7表达存在明显异质性。Objective To explore the heterogeneous expressions of AR-V7 in metastatic castration-resistant prostate cancer(mCRPC)tissues from different metastatic foci from 3 patients.Methods AR-V7 immunohistochemical staining was performed on the paraffin-embedded tissues of primary and re-biopsy prostate tissues and metastases after mCRPC.The expressions of AR-V7 in different tumor tissues were assessed.Results There were significant heterogeneities in the AR-V7 expressions in primary and re-biopsy tissues and metastases after mCRPC.Few residual tumor cells were observed in re-biopsy prostate tissues after mCRPC in 2 patients.AR-V7 was nearly negative in the primary biopsy tissues and was heterogeneously expressed between prostate and different metastases after mCRPC from the same patients.Conclusion The clinical progression of mCRPC patients may be caused by the metastatic tumors.The expression of AR-V7 is significantly heterogeneous in different metastatic foci.

关 键 词：mCRPC AR-V7 异质性 阿比特龙 

分 类 号：R737[医药卫生—肿瘤]